Victoria Sales/Ceclor imports
The New York-based firm was the U.S. importer of a shipment of the Lilly antibiotic whose handling by a series of Hong Kong and Singapore trading companies was described in testimony at an April 16 hearing of Chairman Dingell's House Energy & Commerce/Oversight & Investigations subcmte. The shipment was not counterfeit Ceclor, as incorrectly reported in a previous story on the hearing ("The Pink Sheet" April 21, p. 12). Subcmte. staffer Stephen Sims explained the findings of a staff delegation's trip to several Pacific Rim countries. He said in testimony that in Singapore the congressional group "was primarily interested in the shipment of an Eli Lilly antibiotic product, Ceclor, to the United States in the summer and fall of 1985." Sims said in his testimony: "According to the chief pharmacist of Oscar [a Singapore trading company], the company bought Ceclor from the J.L. Morrison Co. in Malaysia, an authorized Lilly distributor. Oscar's purchase was in response to an order form Galaxy International, a Hong Kong trading company. Oscar said that, because sales were low in Malaysia, Morrison was eager to make the sale, even though the volume ordered was obviously too large for Oscar's normal requirements. The Ceclor was delivered personally to Oscar by Morrison's sales manager, who flew with the goods to Singapore. As instructed by Galaxy, Oscar shipped the goods to Victoria Sales in New York".
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.